세계의 비침습성 액체생검 시장 : 유형, 기술, 최종 사용자별 예측(2025-2030년)

The Non-Invasive Liquid Biopsy Market was valued at USD 1.01 billion in 2023, expected to reach USD 1.19 billion in 2024, and is projected to grow at a CAGR of 18.10%, to USD 3.25 billion by 2030.

Non-invasive liquid biopsy is a cutting-edge diagnostic method used for cancer detection and monitoring, providing a less invasive alternative to traditional tissue biopsies. It involves analyzing circulating tumor cells (CTCs), cell-free DNA (cfDNA), or RNA in bodily fluids like blood, offering critical insights into tumor dynamics without the need for surgical procedures. The necessity of non-invasive liquid biopsies lies in their ability to facilitate early cancer detection, monitor treatment efficacy, and detect recurrent disease, addressing the limitations of tissue biopsies, such as sampling bias and potential surgical complications. Their applications span across oncology, personalized medicine, and prenatal testing, with usage in hospitals, diagnostic centers, and academic institutions. Key growth factors include advancements in genomics and proteomics, growing cancer prevalence, and increasing demand for minimally invasive diagnostic techniques. Additionally, the surge in research and development activities and growing awareness about early cancer detection are fueling the market.

However, challenges include high costs, regulatory complexities, and issues related to test sensitivity and specificity. Overcoming these limits will entail developing standardized protocols and demonstrating clinical utility through robust validation studies. Market players should focus on innovation in molecular diagnostic technologies, enhancing test accuracy, and integrating AI and machine learning for data analysis. Partnerships and collaborations between biopharma companies, research institutes, and healthcare providers are vital to leverage expertise and expand market reach. Opportunities exist in expanding applications to other disease types, improving multi-analyte detection, and developing point-of-care liquid biopsy devices. Investing in expanding the understanding of tumor biology and resistance mechanisms could further elevate liquid biopsy as a transformative tool in cancer management. The market is dynamic and competitive, requiring continuous innovation and strategic collaborations to navigate the evolving landscape and maximize business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Non-Invasive Liquid Biopsy Market

The Non-Invasive Liquid Biopsy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidence and prevalence of cancer
  • Increasing preference for noninvasive diagnostic procedures
• Market Restraints
  • High cost associated with advanced non-invasive liquid biopsy
• Market Opportunities
  • Integration of artificial intelligence with non-invasive liquid biopsy
  • Increasing investment for advanced healthcare infrastructure
• Market Challenges
  • Lack of standardization across different techniques and tumor types

Porter's Five Forces: A Strategic Tool for Navigating the Non-Invasive Liquid Biopsy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Non-Invasive Liquid Biopsy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Non-Invasive Liquid Biopsy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Non-Invasive Liquid Biopsy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Non-Invasive Liquid Biopsy Market

A detailed market share analysis in the Non-Invasive Liquid Biopsy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Non-Invasive Liquid Biopsy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Non-Invasive Liquid Biopsy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Non-Invasive Liquid Biopsy Market

A strategic analysis of the Non-Invasive Liquid Biopsy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Non-Invasive Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include Angle PLC, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocept, Inc., DiaCarta, Inc., Epic Sciences Inc., F. Hoffmann-La Roche Ltd., Guardant Health, Inc., Illumina, Inc., Integrated DNA Technologies, Inc., Laboratory Corporation of America Holdings, Lonza Group Ltd., Lucence Diagnostics Pte. Ltd., LungLife AI, Inc., Mdxhealth BV, MedGenome Labs Ltd., Menarini Silicon Biosystems SpA, Merck KGaA, Nonacus Limited, Norgen Biotek Corporation, Oasis Diagnostics Corporation, OraSure Technologies, Inc, QIAGEN GmbH, Thermo Fisher Scientific Inc., and Zymo Research Corp..

Market Segmentation & Coverage

This research report categorizes the Non-Invasive Liquid Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Assay Kits, Instruments, and Services.
• Based on Technology, market is studied across Next Generation Sequencing (NGS) and RT-PCR and dPCR.
• Based on End-user, market is studied across Academic & Research Centers, Clinical Diagnostic Laboratories, and Hospital.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence and prevalence of cancer
    • 5.1.1.2. Increasing preference for noninvasive diagnostic procedures
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with advanced non-invasive liquid biopsy
  • 5.1.3. Opportunities
    • 5.1.3.1. Integration of artificial intelligence with non-invasive liquid biopsy
    • 5.1.3.2. Increasing investment for advanced healthcare infrastructure
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of standardization across different techniques and tumor types
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Non-Invasive Liquid Biopsy Market, by Type

• 6.1. Introduction
• 6.2. Assay Kits
• 6.3. Instruments
• 6.4. Services

7. Non-Invasive Liquid Biopsy Market, by Technology

• 7.1. Introduction
• 7.2. Next Generation Sequencing (NGS)
• 7.3. RT-PCR and dPCR

8. Non-Invasive Liquid Biopsy Market, by End-user

• 8.1. Introduction
• 8.2. Academic & Research Centers
• 8.3. Clinical Diagnostic Laboratories
• 8.4. Hospital

9. Americas Non-Invasive Liquid Biopsy Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Non-Invasive Liquid Biopsy Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Non-Invasive Liquid Biopsy Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Angle PLC
• 2. Bio-Rad Laboratories, Inc.
• 3. Bio-Techne Corporation
• 4. Biocept, Inc.
• 5. DiaCarta, Inc.
• 6. Epic Sciences Inc.
• 7. F. Hoffmann-La Roche Ltd.
• 8. Guardant Health, Inc.
• 9. Illumina, Inc.
• 10. Integrated DNA Technologies, Inc.
• 11. Laboratory Corporation of America Holdings
• 12. Lonza Group Ltd.
• 13. Lucence Diagnostics Pte. Ltd.
• 14. LungLife AI, Inc.
• 15. Mdxhealth BV
• 16. MedGenome Labs Ltd.
• 17. Menarini Silicon Biosystems SpA
• 18. Merck KGaA
• 19. Nonacus Limited
• 20. Norgen Biotek Corporation
• 21. Oasis Diagnostics Corporation
• 22. OraSure Technologies, Inc
• 23. QIAGEN GmbH
• 24. Thermo Fisher Scientific Inc.
• 25. Zymo Research Corp.